Jefferies Initiates Coverage On Nurix Therapeutics with Buy Rating, Announces Price Target of $41

Benzinga · 10/11 12:02
Jefferies analyst Roger Song initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Buy rating and announces Price Target of $41.